期刊
CANCER TREATMENT REVIEWS
卷 100, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2021.102288
关键词
TILs; TCR-engineered T cells; CAR-T cells; LAK cells; CIK cells; Adoptive immunotherapy
类别
资金
- Associazione Italiana per la Ricerca sul Cancro[MFAG] [23583]
- Italian Ministry of Health
- Associazione per la Ricerca Bio-molecolare Onlus, Acquaviva, Italy [2020]
While various systemic treatments are available for advanced cancers of the digestive tract, none are curative. Clinical trials over the past two decades have investigated different types of T-cell therapies in patients with digestive tract malignancies, with varying degrees of success. Future research will focus on the antitumor potential of adoptive T-cell immunotherapy.
Multiple systemic treatments are currently available for advanced cancers of the digestive tract, but none of them is curative. Adoptive T-cell immunotherapy refers to the extraction, modification and re-infusion of autologous or allogenic T lymphocytes for therapeutic purposes. A number of clinical trials have investigated either non engineered T cells (i.e., lymphokine-activated killer cells, cytokine induced killer cells, or tumor-infiltrating lymphocytes) or engineered T cells (T cell receptor-redirected T cells or chimeric antigen receptor T cells) in patients with digestive tract malignancies over the past two decades, with variable degrees of success. While the majority of completed trials have been primarily aimed at assessing the safety of T-cell transfer strategies, a new generation of studies is being designed to formally evaluate the antitumor potential of adoptive T-cell immunotherapy in both the metastatic and adjuvant settings. In this review, we provide an overview of completed and ongoing clinical trials of passive T-cell immunotherapy in patients with cancers of the digestive tract, focusing on present obstacles and future strategies for achieving potential success.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据